Background: In Greece, pneumococcal conjugate vaccines (PCVs) became sequentially available: 7-valent in October 2004, 10-valent in May 2009, 13-valent in June 2010 and 15-valent in March 2023; soon after availability all vaccines were incorporated in the National Ιmmunization Program except for PCV7 which was implemented in January 2006. Since July 2010, PCV13 has been the most commonly used PCV. Surveillance at a regional and a national level is a valuable tool to monitor the impact of PCVs.
Methods: At the University General Hospital of Larissa (single academic tertiary care referral center for Central Greece) we prospectively obtained samples from 0 to 15-year-old children consequently diagnosed with invasive pneumococcal disease (IPD) or acute otitis media (AOM) with spontaneous perforation of the tympanic membrane (SPTM) during three time periods: the PCV7 (2005-2010), the early-mid PCV13 (2011-2016) and the late PCV13 (2017-2024) periods. Pneumococci were serotyped by capsular swelling. PCR was applied on pleural fluid and CSF specimens.
Results: A total of 106 (61 IPD and 45 AOM with SPTM) serotype-evaluable samples were obtained. Serotypes 19A and 19F peaked in 2005-2010 and decreased thereafter. Increased number of IPD cases due to serotype 3 were noted in the 2011-2016 and 2017-2024 periods. The emergence of non-PCV13 serotypes in IPD and AOM with SPTM was noted in the late PCV13 period. In 2017-2024 the most common serotypes responsible for IPD were 3 and 12F. The projected additional protection from IPD, beyond that of PCV13, offered by PCV15 and PCV20 during 2017-2024 was 10 % and 30 %, respectively. The respective additional protection from AOM offered by the two vaccines was 0 % and 21.4 %.
Conclusion: Our findings in Central Greece suggest that PCVs of increasing valency are expected to provide substantial additional coverage for pneumococcal disease as compared to PCV13.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126765 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pneumococcal genotype 23B1 as a driver of increased 23B serotype carriage, penicillin non-susceptibility, and invasive disease in Belgium: a retrospective analysis.
J Clin Microbiol
March 2025
Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
serotype 23B, a non-vaccine serotype, has shown an increasing prevalence and penicillin non-susceptibility among carriage and invasive pneumococcal disease (IPD) isolates. Recently, a novel penicillin non-susceptible genotype has emerged, named 23B1. In the framework of the Belgian pneumococcal carriage study, we studied the prevalence of 23B/23B1 among 586 23B strains (2016-2022) in 172 day care centers from 6- to 30-month-old children and among 130 pediatric 23B IPD isolates (2007-2021).
View Article and Find Full Text PDFPrevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study.
Contemp Clin Trials Commun
April 2025
Department of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, France.
Background: causes infections especially in patients with immunodeficiency or specific comorbidities. Most could be avoided through pneumococcal vaccination (PV), but PV coverage is only 20 % in France. Many studies assess methods on vaccination coverage improvement, but none evaluates pharmacist-physician collaboration in hospital on PV coverage of inpatients at-risk of invasive pneumococcal disease (IPD).
View Article and Find Full Text PDFUse of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome - a case-series report.
BMC Pediatr
March 2025
Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Nagyerdei Krt 98, 4028, Debrecen, Hungary.
Background: Hemolytic uremic syndrome (HUS), characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury (AKI), remains a leading cause of pediatric AKI. The complement system has a crucial role in the pathogenesis of atypical hemolytic uremic syndrome (aHUS) and eculizumab (ECZ) was approved as standard of care for its treatment. The two widely characterized forms of infection-associated HUS are Shiga toxin-producing E.
View Article and Find Full Text PDFChildhood invasive pneumococcal disease and acute otitis media in Central Greece during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
Vaccine
March 2025
Department of Pediatrics, School of Medicine, University of Thessaly, Larissa, Greece. Electronic address:
Background: In Greece, pneumococcal conjugate vaccines (PCVs) became sequentially available: 7-valent in October 2004, 10-valent in May 2009, 13-valent in June 2010 and 15-valent in March 2023; soon after availability all vaccines were incorporated in the National Ιmmunization Program except for PCV7 which was implemented in January 2006. Since July 2010, PCV13 has been the most commonly used PCV. Surveillance at a regional and a national level is a valuable tool to monitor the impact of PCVs.
View Article and Find Full Text PDFHigh Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021.
Pediatr Infect Dis J
March 2025
From the Pediatrics Department, Jean Verdier Hospital, Assistance Publique-Hôpitaux de Paris, Bondy, France.
Background: Sickle cell disease (SCD) predisposes children to bacterial infections, particularly invasive pneumococcal disease. Pneumococcal immunization associated with antibiotic prophylaxis reduced the incidence of invasive pneumococcal disease in these patients. However, the risk remains higher than in the general population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!